Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

4.57USD
24 Mar 2017
Change (% chg)

$0.10 (+2.24%)
Prev Close
$4.47
Open
$4.50
Day's High
$4.59
Day's Low
$4.48
Volume
4,878,834
Avg. Vol
6,181,319
52-wk High
$7.15
52-wk Low
$2.54

Select another date:

Wed, Mar 1 2017

BRIEF-Synergy Pharmaceuticals reports qtrly net loss per common share $0.31

* Synergy Pharmaceuticals reports fourth quarter and full year 2016 financial results and business update

BRIEF-Synergy Pharmaceuticals provides update on phase 3 data results for Trulance

* Pivotal phase 3 data results for Trulance(Tm) (plecanatide) in the treatment of chronic idiopathic constipation (CIC) published in American Journal Of Gastroenterology

Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)

CORRECTED-UPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19)

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

BRIEF-Synergy Pharma's Trulance receives FDA approval for treatment of adults with chronic idiopathic constipation

* Synergy Pharmaceuticals' Trulance(TM) (Plecanatide) receives U.S. FDA approval for the treatment of adults with chronic idiopathic constipation

Synergy wins U.S. approval for constipation drug

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC). (http://bit.ly/2k5wNlA)

BRIEF-FDA approves Trulance for chronic idiopathic constipation

* FDA- Trulance is manufactured by New York, New York-based Synergy Pharmaceuticals Inc Source text for Eikon: Further company coverage:

Synergy Pharma's irritable bowel drug succeeds in key study

Synergy Pharmaceuticals Inc said its experimental once-daily tablet, plecanatide, met the main goal of a late-stage study on irritable bowel syndrome patients with constipation (IBS-C), according to an analysis of preliminary data.

BRIEF-Synergy Pharma enters privately-negotiated exchange agreements

* Synergy Pharma-co entered privately-negotiated exchange agreements with certain holders of co's 7.50% convertible senior notes due 2019

BRIEF-Synergy Pharmaceuticals Inc reports qtrly loss per share of $0.22

* Synergy Pharmaceuticals reports third quarter 2016 financial results and business update Source text for Eikon: Further company coverage:

Select another date:

More From Around the Web